Track topics on Twitter Track topics that are important to you
Zacks Investment Research currently has $1.75 price target on the biopharmaceutical company's stock. According to Zacks, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life.
Original Article: Athersys, Inc. (ATHX) Upgraded to Buy by Zacks Investment ResearchNEXT ARTICLE
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...